Cell Therapeutics Readies Commercial Launch of Pixuvri® in EU ... MarketWatch (press release) CTI is currently accruing patients into a Phase III trial comparing pixantrone and rituximab with gemcitabine and rituxan in the setting of aggressive B-cell ... |
